title: Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE.
abstract: BACKGROUND
  Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life.
  
  
  OBJECTIVE
  To investigate to what extent treatment decisions made by dermatologists in daily clinical practice for patients with psoriasis on biologics are already in accordance with treatment goals without the active application of the treatment goals algorithm.
  
  
  METHODS
  Data were extracted from a prospective daily practice cohort of patients with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). Treatment decisions such as dosage adjustments, combination treatments, or switching therapy were compared with the treatment goals algorithm.
  
  
  RESULTS
  In 64% (253 of 395) of visits, physicians followed the treatment goals algorithm. There were 162 (41%) visits in which there should have been a treatment modification according to treatment goals (group Modify) and a modification was indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment modification was necessary (group Continue) and therapy was indeed not modified in 194 of 233 visits (83%).
  
  
  CONCLUSIONS
  Physicians acted in accordance with treatment goals in the majority of patient visits. In the patient group not achieving these goals, physicians should have modified therapy according to treatment goals but continued the same therapeutic regimen in the majority of visits. Optimizing therapy and defining barriers in the latter group might increase treatment results in daily practice psoriasis care.
authors.affiliation: Department of Dermatology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, René Descartesdreef 1, Nijmegen, 6525 GL, the Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Zweegers
authors.forename: J M P A
authors.initials: JM
authors.lastname: van den Reek
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: M E
authors.initials: ME
authors.lastname: Otero
authors.forename: P M
authors.initials: PM
authors.lastname: Ossenkoppele
authors.forename: M D
authors.initials: MD
authors.lastname: Njoo
authors.forename: J M
authors.initials: JM
authors.lastname: Mommers
authors.forename: M I A
authors.initials: MI
authors.lastname: Koetsier
authors.forename: W P
authors.initials: WP
authors.lastname: Arnold
authors.forename: B A M
authors.initials: BA
authors.lastname: Sybrandy-Fleuren
authors.forename: A L A
authors.initials: AL
authors.lastname: Kuijpers
authors.forename: M P M
authors.initials: MP
authors.lastname: Andriessen
authors.forename: W
authors.initials: W
authors.lastname: Kievit
authors.forename: E M G J
authors.initials: EM
authors.lastname: de Jong
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use*; D003657:Decision Making; D003879:Dermatologic Agents / Q000627:therapeutic use*; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006040:Goals; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001685:Biological Factors; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept